DEF: Heron Therapeutics Seeks Shareholder Approval for Conversions

Heron Therapeutics is seeking shareholder approval for the potential issuance of common stock exceeding 19.99% of current outstanding shares, stemming from the conversion of convertible senior unsecured promissory notes and Series A Convertible Preferred Stock.

Summary

• A Special Meeting of Stockholders will be held on October 13, 2025, at 9:00 a.m. Eastern Time, exclusively via the Internet.
• Stockholders will vote on Proposal 1: To approve the issuance of common stock upon conversion of convertible senior unsecured promissory notes due 2031, which could exceed 19.99% of outstanding shares, as required by Nasdaq Listing Rule 5635(d).
• Stockholders will vote on Proposal 2: To approve the issuance of common stock upon conversion of Series A Convertible Preferred Stock, which could exceed 19.99% of outstanding shares, as required by Nasdaq Listing Rule 5635(d).
• The Record Date for stockholders entitled to vote at the Special Meeting is September 11, 2025.
• As of the Record Date, there were 183,314,409 shares of the Company's Common Stock outstanding and entitled to vote.
• The Board of Directors recommends a vote FOR both Proposal 1 and Proposal 2.
• If Proposal 1 is not approved, the Company will be obligated to repay the convertible notes in cash with interest, which would have a material, adverse impact on liquidity and cash available for business operations.
• If Proposal 2 is not approved, the Series A Convertible Preferred Stock will not be convertible into Common Stock and will remain outstanding.

Sentiment

Score: 6

Explanation: The filing is procedural, seeking shareholder approval for financing transactions that have already occurred. While the financing provides necessary capital, the potential for significant shareholder dilution is a negative factor. The Board's recommendation for approval suggests these are necessary steps for the company's financial health, making the overall sentiment neutral to slightly positive as it enables the execution of a capital strategy.

Positives

• The proposals, if approved, facilitate the conversion of debt and preferred stock into equity, potentially strengthening the balance sheet by reducing future cash repayment obligations for the convertible notes.
• The Company completed refinancing transactions on August 8 and August 12, 2025, indicating successful capital restructuring efforts.
• The Convertible Note Issuance raised $33.25 million from Rubric Capital Management LP for $35.0 million aggregate principal amount of notes.
• A Private Placement generated approximately $27.7 million through the sale of common stock and Series A Convertible Preferred Stock.

Negatives

• Approval of the proposals could lead to significant dilution for current stockholders, as the new shares issued upon conversion may exceed 19.99% of the number of shares outstanding prior to such issuance.
• Dilution may cause a reduction in current stockholders' percentage interests in voting power, liquidation value, book and market value, and future earnings.
• The issuance or resale of the additional shares of Common Stock could cause the market price of the Company's Common Stock to decline.
• An increased number of shares issued could discourage or make more difficult certain mergers, tender offers, proxy contests, or other change of control or ownership transactions.
• Non-approval of Proposal 1 would result in a material, adverse impact on the Company's liquidity and cash due to the obligation to repay the convertible notes in cash with interest.

Risks

• Significant dilution of current stockholders' ownership and voting power if the share issuance proposals are approved.
• Potential decline in the market price of Common Stock due to the increased number of shares outstanding following conversions.
• Material adverse impact on the Company's liquidity and cash available for operations if Proposal 1 (Notes Stock Issuances) is not approved, requiring cash repayment of notes.
• Increased difficulty for future mergers, tender offers, proxy contests, or other change of control transactions due to a higher share count.

Future Outlook

If stockholders approve the proposals, the Company will be authorized to issue common stock upon conversion of the convertible notes and Series A Convertible Preferred Stock, which could significantly increase the number of outstanding shares. If Proposal 1 is not approved, the Company will be obligated to repay the notes in cash with interest, leading to a material adverse impact on liquidity. If Proposal 2 is not approved, the Series A Convertible Preferred Stock will remain outstanding and not convert to common stock.

Management Comments

• The Board of Directors recommends a vote FOR the Notes Stock Issuance, including an amount above 19.99% of the number of shares of the Company's Common Stock issued and outstanding prior to such issuance.
• The Board of Directors recommends a vote FOR the Preferred Stock Issuance, including an amount above 19.99% of the number of shares of the Company's Common Stock issued and outstanding prior to such issuance.

Industry Context

This filing reflects a common strategy for publicly traded companies, particularly in capital-intensive sectors like biotechnology, to manage their capital structure and liquidity. The need for shareholder approval under Nasdaq Listing Rule 5635(d) for significant equity issuances is a standard regulatory requirement. The refinancing transactions indicate a proactive approach to restructure existing debt and secure additional capital, a frequent occurrence in industries requiring substantial investment in research, development, and commercialization.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for significant dilution of ownership, voting power, and value per share if proposals are approved. Risk of market price decline. If Proposal 1 is not approved, company liquidity could be materially adversely impacted, which would negatively affect shareholder value.
• Creditors (Convertible Note Holders): If Proposal 1 is approved, they gain the option to convert debt into equity. If not approved, the Company will be obligated to repay them in cash with interest.
• Preferred Stock Holders: If Proposal 2 is approved, their preferred stock will automatically convert into common stock. If not approved, their preferred stock remains outstanding.

Next Steps

• Stockholders are to vote on Proposal 1 (approval of share issuance for convertible notes) by the proxy deadline of October 12, 2025, or during the Special Meeting on October 13, 2025.
• Stockholders are to vote on Proposal 2 (approval of share issuance for Series A Convertible Preferred Stock) by the proxy deadline of October 12, 2025, or during the Special Meeting on October 13, 2025.
• The Company expects to file a Current Report on Form 8-K within four business days after the Special Meeting to publish preliminary or final voting results.
• If approved, the Convertible Senior Unsecured Promissory Notes will be convertible into Common Stock from the later of stockholder approval or December 31, 2025.
• If approved, the Series A Convertible Preferred Stock will automatically convert into Common Stock.

Key Dates

Recommendation

This filing is a procedural step to gain shareholder approval for share issuances related to previously announced refinancing transactions. While the potential for significant dilution exists, this was inherent in the original financing agreements. A 'FOR' vote is crucial to avoid a material adverse impact on the company's liquidity, which would be detrimental to all shareholders. An investor would likely 'Hold' as the core financial strategy has been set, and this vote is about enabling its execution rather than a new strategic direction or fundamental change in the investment thesis.

Keywords

Heron Therapeutics, HRTX, SEC Filing, Proxy Statement, Special Meeting, Stockholder Approval, Convertible Notes, Preferred Stock, Share Issuance, Dilution, Nasdaq Listing Rule 5635(d), Capital Raise, Refinancing, Corporate Governance